Crizotinib CAS 877399-52-5 Assay ≥99.0% API Factory Kona Kiʻekiʻe
ʻO Shanghai Ruifu Chemical Co., Ltd. ka mea hana nui o Crizotinib (CAS: 877399-52-5) me ke kūlana kiʻekiʻe.Hiki iā Ruifu Chemical ke hāʻawi aku i ka honua holoʻokoʻa, ke kumukūʻai hoʻokūkū, ka lawelawe maikaʻi loa, ka liʻiliʻi a me ka nui nui i loaʻa.Kūʻai iā Crizotinib,Please contact: alvin@ruifuchem.com
| Inoa Kimia | ʻO Crizotinib |
| Nā huaʻōlelo like | Xalkori;PF-02341066;Crozotinib;Crizotinib Xalkori;3-[1-(2,6-Dichloro-3-Fluoro-phenyl)-ethoxy]-5-(1-Piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine;(R)-3-[1-(2,6-Dichloro-3-Fluorophenyl)ethoxy]-5-(1-Piperidin-4-yl-1H- pyrazol-4-yl)pyridin-2-ylamine |
| Helu CAS | 877399-52-5 |
| Kūlana Kūʻai | Ma ka waihona, ʻoi aku ka nui o ka hana a hiki i nā haneli kilogram |
| ʻĀpana Molekala | C21H22Cl2FN5O |
| Kaumaha Molecular | 450.34 |
| Lae hehee | 192 ℃ |
| ʻO ka mānoanoa | 1.47±0.10 g/cm3 |
| Ka Mahana Waihona | Ka Mahana lumi |
| Ke kumu | Shanghai, Kina |
| Brand | Kemika Ruifu |
| 'ikamu | Nā kikoʻī |
| Ka nana aku | Keʻokeʻo a hiki i ka pauda keʻokeʻo |
| ʻIkepili | Na IR, HPLC |
| Akaka o ka Haʻina | Kūlike me ke Kūlana |
| Nalo ma ka maloo | ≤1.00% |
| Koena ma ka Ignition | ≤0.50% |
| Nā mea haumia pili | (na HPLC) |
| Hoʻokahi haumia | ≤0.50% |
| Huina paumaele | ≤1.00% |
| Nā Metala Kaumaha | ≤20ppm |
| Hoʻāʻo | ≥99.0% |
| Nā mea hoʻoheheʻe koena | E hālāwai me ka wehewehe |
| Ola Pahu | 24 mahina |
| Kūlana hoʻāʻo | Kūlana ʻoihana |
Pūʻolo:ʻO ka ʻōmole, ʻeke ʻeke alumini, 25kg / pahu pahu pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.
Kūlana mālama:E hoʻopaʻa paʻa i ka pahu a mālama i loko o kahi hale kūʻai maloʻo a maloʻo (2 ~ 8 ℃) a me kahi hale kūʻai maikaʻi mai nā mea like ʻole.E pale i ka malamalama a me ka wai.
Hoʻouna:Hāʻawi i ka honua ma ka lewa, e FedEx / DHL Express.Hāʻawi wikiwiki a hilinaʻi hoʻi.
ʻO ka wehewehe palekana 24/25 - E pale i ka pili ʻana me ka ʻili a me nā maka.
Nā ID UN UN 3077 9 / PGIII
WGK Kelemānia 3
HS Code 2933990099
PILI PILI
ʻO Crizotinib (CAS 877399-52-5), (Crizotinib, Xalkori R), he mea hoʻokūkū ikaika ATP hoʻokūkū liʻiliʻi o ALK a me c-Met.I ʻAukake 2011, ua ʻae ka FDA o ʻAmelika Hui Pū ʻIa iā Crizotinib no ka mālama ʻana i ka lymphoma kinase (ALK) anaplastic lymphoma kinase (ALK) i hoʻonohonoho hou ʻia i ka maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi (NSCLC).ʻO Crizotinib kahi mea hoʻokūkū hoʻokūkū ʻelua ATP o tyrosine kinases c-MET (Mesenchymal-Epithelial Transition Factor) kinase (cellular IC50 = 8 nM) a me ALK (cellular IC50 = 20 nM), ʻo ia mau mea ʻelua mau pahuhopu nui no ka chemotherapy maʻi.I ka wā i hoʻāʻo ʻia ai ka crizotinib no ke koho ʻana me nā kinase ʻē aʻe, ua ʻike ʻia aia ka enzyme IC50 i loko o 100-fold multiples o c-MET no 13 o nā kinase 120 i hoʻāʻo ʻia.I loko o ka cellular assays, ua ʻike ʻia ka crizotinib e kāohi i ka RON (recepteur d'origine nantais) kinase me kahi puka koho koho 10-fold ma luna o c-MET.
ʻO Crizotinib (PF-02341066) ʻO Crizotinib he mea ikaika c-Met a me ALK inhibitor, ʻo nā waiwai IC50 i ka cell assay he 11 nM a me 24 nM.He mea paakiki no hoi ia o ROS1 me ka waiwai Ki malalo o 0.025 nM.Hiki i ka Crizotinib ke hoʻoulu i ka autophagy i nā ʻano laina maʻi maʻi maʻi maʻi ma o ke kāohi ʻana i ke ala STAT3.
ʻO Crizotinib kahi mea paʻa a koho ʻelua o ka mesenchymal-epithelial transition factor (c-MET) kinase a me anaplastic lymphoma kinase (ALK).ʻO Crizotinib kahi lāʻau antitumor.I ʻAukake 2011, ua ʻae ka FDA o ʻAmelika Hui Pū ʻIa i ka crizotinib no ka mālama ʻana i ka anaplastic lymphoma kinase (ALK) i hoʻonohonoho hou ʻia i ka maʻi maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi (NSCLC).
ʻO Crizotinib (Xalkori(R), Pfizer), i ʻāpono ʻia i ka makahiki 2011, ʻo ia ka mea hoʻopaneʻe mua i ʻae ʻia e huli ana i ka anaplastic lymphoma kinase (ALK).ʻO ROS protooncogene 1-encoded kinase (ROS1) o ka tyrosine kinase insulin receptor class a me MET proto-oncogene-encoded kinase o ka hepatocyte growth factor receptor (HGFR) he mau kinase ʻē aʻe i manaʻo ʻia e crizotinib. lāʻau lapaʻau e kuhikuhi pono ana i nā maʻi NSCLC.Eia nō naʻe, ʻike pinepine ʻia ke kūʻē ʻana i ka crizotinib ma kahi o 8 mau mahina ma hope o ka noi mua ʻana a ʻoi aku ma mua o ka hapalua o nā maʻi i mālama ʻia i ka crizotinib i ʻike i nā hopena ʻaoʻao o ka ʻōpū.I ka makahiki 2016, ua ʻae ʻia ʻo crizotinib no ROS1-positive NSCLC e FDA.
ʻO Crizotinib (Xalkori) he mea hoʻopaneʻe waha ʻo tyrosine kinase inhibitor i hōʻike ʻia no ka mālama ʻana i nā poʻe maʻi me ka maʻi maʻi maʻi maʻi maʻi ʻaʻole liʻiliʻi liʻiliʻi (NSCLC).ʻO nā hopena ʻaoʻao maʻamau me ka hoʻohana ʻana iā Xalkori, ʻo ia ka maʻi hanu kiʻekiʻe, nausea, luaʻi, ʻeha o ka ʻōpū, hoʻemi i ka ʻai, insomnia, dizziness, manaʻo luhi, maʻi maʻi, constipation, ʻūhū a ʻāʻī paha, nā hōʻailona anu (ka ihu ihu, ʻāhu, ʻeha ʻeha), ʻeha a i ʻole. ka ʻūhū, a i ʻole ka pehu ʻana i kou mau lima a i ʻole nā wāwae.
